OQL06x

OQL06x is a gut-restricted Janus kinase (JAK) inhibitor being developed by OnQuality Pharmaceuticals as a first-in-disease drug candidate for the treatment of diarrhea induced by epidermal growth factor receptor (EGFR) inhibitors. EGFR inhibitor-induced diarrhea is a common and often severe side effect of cancer therapies that can lead to treatment discontinuation, dehydration, and electrolyte imbalance. OQL06x is designed to remain localized within the gastrointestinal tract, thereby providing targeted therapeutic action while minimizing the systemic exposure and potential toxicities typically associated with systemic JAK inhibitors. The drug was developed using OnQuality's AI-enabled CARE platform, which focuses on identifying and developing supportive therapies for oncology-related side effects.